Xeris Pharmaceuticals | XERS - Ebitda



金融业
股票价格
USD
资产
USD 392.01M
现金及等价物
USD 111.75M
销售成本
USD 13.66M
流动资产
USD 251.68M
流动负债
USD 118.59M
债务
USD 257.65M
EBIT
USD 16.77M
EBITDA
USD 25.09M
员工
377
EPS每股收益
USD 0.01
股本和储备
USD 13.01M
销售毛利
USD 72.15M
债务利息支出
USD 7.15M
利息收入
USD 1.16M
贷款资金
USD 221.22M
市值
USD 875M
净收入
USD 11.08M
营业费用
USD 69.03M
营业利润
USD 16.77M
普通股股本
USD 166.22M
PE价格收益
2.45K
税前利润
USD 11.08M
销售收入
USD 83.13M
销售和管理费用
USD 42.64M
股票
USD 74.23M
贸易债权人
USD 11.47M
应收帐款人
USD 51.05M


Ebitda 更改 日
Celltrion KRW 17.79B 356.77B 2025-12
Cspc Pharmaceutical CNY 2.19B 21.88M 2024-12
Deva Holding AS TRY 882.9M 201.7M 2023-09
Dianthus Therapeutics USD -40.19M 5.36M 2025-09
Divis Laboratories Ltd INR 9.34B 440M 2026-03
Eli Lilly USD 12.14B 4.26B 2025-12
Kangmei Pharma CNY 17.3M 20.56M 2025-06
Knight Therapeutics CAD 24.45M 3.46M 2025-12
Laboratorios Farma EUR 34.94M 102.95M 2025-06
Malin Corporation EUR -1.1M 200K 2024-12
Medical Developments International AUD 1.78M 3.78M 2024-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Neuren Pharmaceuticals AUD 11.14M 165.56M 2025-12
Organigram Holdings CAD 5.26M 884K 2025-12
Pacira USD 40.24M 1.53M 2026-03
Perrigo USD 141.6M 1.34B 2026-03
Pharma Mar EUR 2.71M 42.25M 2026-03
Qiagen NV USD 249.69M 56.53M 2025-12
Sartorius EUR 267.3M 10.1M 2026-03
Sino Biopharmaceutical CNY 2.59B 1.57B 2024-12
Supernus Pharmaceuticals USD 29.23M 19.27M 2026-03
Tilray USD 8.36M 1.82M 2025-09
Zealand Pharma A/S -727.47M 285.54M 2025-12
Zhangzhou Pientzehuang Pharmaceutical CNY 882.7M 351.1M 2026-03